About Syros Pharmaceuticals (NASDAQ:SYRS)
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SYRS
CUSIPN/A
Phone617-744-1340
Debt
Debt-to-Equity RatioN/A
Current Ratio5.89%
Quick Ratio5.89%
Price-To-Earnings
Trailing P/E Ratio-5.90
Forward P/E Ratio-5.66
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.10 million
Price / Sales367.55
Cash FlowN/A
Price / CashN/A
Book Value$2.40 per share
Price / Book5.23
Profitability
EPS (Most Recent Fiscal Year)($2.13)
Net Income$-54,010,000.00
Net MarginsN/A
Return on Equity-70.81%
Return on Assets-62.77%
Miscellaneous
Employees56
Outstanding Shares32,190,000
Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions
What is Syros Pharmaceuticals' stock symbol?
Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."
How were Syros Pharmaceuticals' earnings last quarter?
Syros Pharmaceuticals (NASDAQ:SYRS) released its earnings results on Monday, March, 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.57) by $0.01. View Syros Pharmaceuticals' Earnings History.
When is Syros Pharmaceuticals' next earnings date?
What price target have analysts set for SYRS?
8 brokerages have issued twelve-month price targets for Syros Pharmaceuticals' stock. Their forecasts range from $10.00 to $33.00. On average, they expect Syros Pharmaceuticals' stock price to reach $22.4286 in the next year. View Analyst Ratings for Syros Pharmaceuticals.
What are Wall Street analysts saying about Syros Pharmaceuticals stock?
Here are some recent quotes from research analysts about Syros Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. " (1/20/2018)
- 2. Cann analysts commented, "Syros announced today that FDA has granted orphan drug designation to SY-1425 for the treatment of acute myeloid leukemia (AML). FDA’s Office of Orphan Drug Products grants orphan status to support development of medicines for the treatment of rare diseases that affect fewer than 200,000 people in the United States. Orphan drug designation may provide certain benefits, including a seven-year period of market exclusivity if the drug is approved, tax credits for qualified clinical trials and an exemption from FDA application fees." (8/21/2017)
Who are some of Syros Pharmaceuticals' key competitors?
Some companies that are related to Syros Pharmaceuticals include Collegium Pharmaceutical (COLL), Mirati Therapeutics (MRTX), Eagle Pharmaceuticals (EGRX), Deciphera Pharmaceuticals (DCPH), Urogen Pharma (URGN), CymaBay Therapeutics (CBAY), OptiNose (OPTN), Vanda Pharmaceuticals (VNDA), Adamas Pharmaceuticals (ADMS), GlycoMimetics (GLYC), Karyopharm Therapeutics (KPTI), NuCana (NCNA), Omeros (OMER), ANI Pharmaceuticals (ANIP), Dova Pharmaceuticals (DOVA), AMAG Pharmaceuticals (AMAG), Rocket Pharmaceuticals (RCKT) and Endocyte (ECYT).
Who are Syros Pharmaceuticals' key executives?
Syros Pharmaceuticals' management team includes the folowing people:
- Dr. Nancy A. Simonian, Pres, CEO & Director (Age 57)
- Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 64)
- Mr. Gerald E. Quirk, Chief Legal & Admin. Officer and Sec. (Age 50)
- Dr. David A. Roth M.D., Chief Medical Officer (Age 55)
- Dr. Nathanael S. Gray Ph.D., Scientific Founder and Member of Scientific Advisory Board
When did Syros Pharmaceuticals IPO?
(SYRS) raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Has Syros Pharmaceuticals been receiving favorable news coverage?
Press coverage about SYRS stock has trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Syros Pharmaceuticals earned a media sentiment score of 0.19 on Accern's scale. They also assigned news coverage about the company an impact score of 46.43 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Syros Pharmaceuticals?
Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syros Pharmaceuticals' stock price today?
One share of SYRS stock can currently be purchased for approximately $12.56.
How big of a company is Syros Pharmaceuticals?
Syros Pharmaceuticals has a market capitalization of $420.45 million and generates $1.10 million in revenue each year. The company earns $-54,010,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Syros Pharmaceuticals employs 56 workers across the globe.
How can I contact Syros Pharmaceuticals?
Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]
MarketBeat Community Rating for Syros Pharmaceuticals (SYRS)
MarketBeat's community ratings are surveys of what our community members think about Syros Pharmaceuticals and other stocks. Vote "Outperform" if you believe SYRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Syros Pharmaceuticals (NASDAQ:SYRS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Syros Pharmaceuticals (NASDAQ SYRS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 33.60%
Institutional Ownership Percentage: 49.33%
Syros Pharmaceuticals (NASDAQ SYRS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/31/2018 | Srinivas Akkaraju | Director | Buy | 209,424 | $9.55 | $1,999,999.20 | |  |
| 12/15/2017 | Jeremy P Springhorn | Insider | Buy | 15,000 | $9.08 | $136,200.00 | | |
| 12/14/2017 | Srinivas Akkaraju | Director | Buy | 109,774 | $9.03 | $991,259.22 | | |
| 10/23/2017 | Colleen Elizabeth Desimone | Insider | Sell | 550 | $16.06 | $8,833.00 | | |
| 8/14/2017 | Richard A Young | Director | Sell | 3,282 | $22.00 | $72,204.00 | 420,101 | |
| 8/7/2017 | Eric R Olson | Insider | Sell | 2,500 | $23.59 | $58,975.00 | 2,500 | |
| 7/25/2017 | Eric R Olson | Insider | Sell | 12,500 | $21.85 | $273,125.00 | 12,500 | |
| 7/25/2017 | Richard A Young | Director | Sell | 3,282 | $22.09 | $72,499.38 | 423,383 | |
| 7/6/2016 | Redmile Group, Llc | Major Shareholder | Buy | 432,746 | $12.50 | $5,409,325.00 | | |
| 7/6/2016 | Robert Nelsen | Director | Buy | 400,000 | $12.50 | $5,000,000.00 | | |
(Data available from 1/1/2013 forward)
Syros Pharmaceuticals (NASDAQ SYRS) News Headlines
| Source: |
|
Syros Pharmaceuticals (NASDAQ:SYRS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Syros Pharmaceuticals (NASDAQ SYRS) Stock Chart for Saturday, April, 21, 2018
Loading chart…
